MD : NYSE : Health Care
$75.31 up 0.13 | 0.17%
Today's Range: 74.72 - 75.42
Avg. Daily Volume: 567,300
07/26/16 - 4:02 PM ET

Financial Analysis


MEDNAX INC's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased. MEDNAX INC has strong liquidity. Currently, the Quick Ratio is 1.70 which shows the ability to cover short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has increased by 16.42% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)752.62639.4
EBITDA ($mil)143.82128.43
EBIT ($mil)124.23114.82
Net Income ($mil)67.968.71


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)64.2856.99
Total Assets ($mil)4636.293646.31
Total Debt ($mil)1442.7897.16
Equity ($mil)2460.412113.23


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin31.0630.71
EBITDA Margin19.120.08
Operating Margin16.5117.96
Sales Turnover0.620.69
Return on Assets7.238.83
Return on Equity13.6315.25
Debt Q1 FY16 Q1 FY15
Current Ratio1.761.79
Debt/Capital0.370.3
Interest Expense14.463.27
Interest Coverage8.5935.15


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)92.9293.45
Div / share0.00.0
EPS0.730.72
Book value / share26.4822.61
Institutional Own % n/a n/a
Avg Daily Volume570981.0856302.0

Valuation


BUY. This stock's P/E ratio indicates a discount compared to an average of 21.90 for the Health Care Providers & Services industry and a discount compared to the S&P 500 average of 25.05. To use another comparison, its price-to-book ratio of 2.86 indicates valuation on par with the S&P 500 average of 2.81 and a discount versus the industry average of 3.34. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, MEDNAX INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MD 21.12 Peers 21.90   MD 18.26 Peers 12.23

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

MD is trading at a valuation on par with its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MD is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MD 16.00 Peers 16.46   MD 1.05 Peers 0.95

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

MD is trading at a valuation on par with its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MD trades at a premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MD 2.86 Peers 3.34   MD 10.12 Peers 22.01

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MD is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MD is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MD 2.44 Peers 0.81   MD 15.17 Peers 14.30

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MD is trading at a significant premium to its industry.

 

Average. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

MD is keeping pace with its peers on the basis of sales growth.

 

 

Latest Stock Upgrades/Downgrades